Neurogene Inc. filed a Form 10-Q with the SEC on November 9, 2026, reporting condensed consolidated financial results for the quarterly period ended September 30, 2026.

Key Highlights

  • Net loss for the nine months ended September 30, 2026: $94,445 thousand, compared with $65,616 thousand for the same period in 2025, according to the filing.
  • Net loss for Q3 2026: $29,023 thousand, or $1.05 per share basic and diluted, versus $20,953 thousand, or $0.99 per share, in Q3 2025.
  • Total assets as of September 30, 2026: $377,901 thousand, up from $288,604 thousand at December 31, 2025.
  • Cash, cash equivalents, and short-term investments: $78,942 thousand in cash and cash equivalents plus $280,776 thousand in short-term investments as of September 30, 2026.
  • July 2026 public offering: The company disclosed issuance of common stock and pre-funded warrants raising net proceeds of $134,877 thousand, with 4,124,999 shares issued.
  • Shares outstanding as of November 5, 2026: 20,700,905 shares of common stock.
  • Accumulated deficit: $447,094 thousand as of September 30, 2026, compared with $352,649 thousand at December 31, 2025.

Neurogene's Financial Position and Operating Results for the Third Quarter of 2026

Neurogene Inc. (NASDAQ:NGNE), a Delaware-incorporated company headquartered in New York, NY, reported a net loss of $29,023 thousand for the three months ended September 30, 2026, according to the filing. Total operating expenses for the quarter were $32,376 thousand, consisting of $23,522 thousand in research and development expenses and $8,854 thousand in general and administrative expenses. For the nine months ended September 30, 2026, total operating expenses reached $102,395 thousand, up from $75,799 thousand in the comparable prior-year period.

The company's balance sheet reflects a significant increase in total assets, rising to $377,901 thousand at September 30, 2026, from $288,604 thousand at December 31, 2025. This increase was supported in part by equity raises during the period. The filing discloses that in Q3 2026 alone, the company raised net proceeds of $134,877 thousand through a public offering of common stock and pre-funded warrants, and an additional $25,889 thousand through at-the-market offerings. Total stockholders' equity stood at $354,794 thousand at the end of the reporting period, compared with $264,887 thousand at December 31, 2025.

Stock-based compensation expense for the nine months ended September 30, 2026 was $16,638 thousand, compared with $10,821 thousand in the same period of 2025. Interest income of $7,545 thousand was recorded for the nine-month period. The weighted-average shares of common stock outstanding, basic and diluted, were 27,695,698 for Q3 2026 and 24,204,232 for the nine months ended September 30, 2026, reflecting the share issuances completed during the year.

What Was Disclosed

Neurogene filed its quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $94,445 thousand, a July 2026 public offering netting $134,877 thousand, and total assets of $377,901 thousand at the reporting date.